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Introduction: Non-invasive, nanosecond, stepwise
two-photon laser excitation of skin tissue was shown
to induce melanin fluorescence spectra that allow for
the differentiation of melanocytic nevi from cutaneous
melanoma.
Methods and analysis: This prospective,
non-controlled, multicentre clinical study is performed
to evaluate the diagnostic performance of the stepwise
two-photon excited melanin fluorescence in the
detection of cutaneous melanoma. The comparator will
be the histopathological diagnosis. A total of 620
pigmented skin lesions suspicious for melanoma and
intended for excision will be enrolled.
Ethics and dissemination: Ethics approval was
provided by the local ethics committees of the medical
faculties of the University of Tuebingen, Heidelberg and
Berlin.




Melanoma is a malignant tumour, which devel-
ops from the pigment producing melanocytes
by neoplastic transformation. Malignant mel-
anoma is identiﬁed as one form of cancer of
increasing incidence, which is now among the
10 most frequent human malignancies. In
Europe, the regional incidence rates reside
between 10 and 25 per 100 000 per year and
increase, especially in elderly people.1–6 After
diagnosis of a malignant melanoma, the
prognosis depends strongly on the thickness of
the tumour and lymphatic or haematogenous
metastases.7 Once melanomas cause metasta-
ses, the prognosis of survival worsens dramatic-
ally, with a 5-year survival of patients with stage
IV disease between 6.7% and 18.8%.8 9 This
underlines the urgent need to diagnose mel-
anoma as early as possible. The diagnostic
accuracy for the clinical melanoma diagnosis
does not exceed 75% and may be increased to
up to 90% by the use of dermoscopy in the
hands of experts; however, ∼10% of melano-
mas will be missed despite all these aforemen-
tioned diagnostic efforts. The term ‘featureless
Strengths and limitations of this study
▪ For the first time, the diagnostic performance of
non-invasive, nanosecond, stepwise two-photon
laser excitation in the detection of melanoma will
be evaluated.
▪ The University of Tuebingen acts as the sponsor
of the study, thus reducing the influence of com-
mercial interests and bias.
▪ The FLIMMA study is designed as a prospective,
multicentre observational study. Histopathologists
are blinded to the results of the test device and a
central review board of histopathologists will review
all false-negative results of the test device. While
randomised controlled trials generate the most reli-
able evidence, the protocol described here is a
necessary preliminary step in this challenging area
of research and was closely adapted from Food and
Drug Administration-approved protocols in the field
of medicinal products for the diagnosis of
melanoma.
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melanoma’ has been coined for this phenomenon.10
Particularly in these difﬁcult to diagnose and ‘featureless’
melanomas, additional strategies for melanoma diagnosis
would be extremely helpful.
Two-step photon excitation of melanin fluorescence
Autoﬂuorescence spectra of human skin tissue are
usually excited by one-photon absorption in the
ultraviolet-A region.11 However, by this form of excita-
tion, the ultra-weak ﬂuorescence of melanin is undetect-
ably hidden by the emission from the main endogenous
ﬂuorophores NAD(P)H and ﬂavins.12 13 A more speciﬁc
excitation of the melanin ﬂuorescence may be useful for
gaining information about the potential malignancy of
pigmented skin lesions. A ﬁrst step to overcome this lack
of speciﬁc melanin ﬂuorescence was the application of
more targeted ﬂuorescence excitation technique based
on two photon absorption from an 800 nm-femtosecond
laser. All endogenous skin tissue ﬂuorophores except
melanin do not absorb at 800 nm; nevertheless, on
irradiation with 800 nm-laser pulses, they may show their
well-known ﬂuorescence in the spectrum of visible light.
This is caused by a special non-linear optical effect
called simultaneous two photon absorption. The inten-
sity of the excited ﬂuorescence is comparably weak. In
contrast, melanin shows absorption on irradiation with
800 nm-laser pulses and absorbs two photons in a step-
wise process via an intermediate excited electronic
state.12 At physiologically acceptable laser intensities, the
latter mechanism is much more effective.14 By this pro-
cedure, the main autoﬂuorescence of skin will be partly
suppressed and the melanin ﬂuorescence becomes
measurable. Investigations in a variety of pigmented skin
lesions gave ﬁrst hints on the differences between the
ﬂuorescence from common nevi as compared to malig-
nant melanoma.15 Also, in other melanin-containing
ﬂuorophore compositions, this ﬂuorescence discrimin-
ation in favour of melanin can be observed, for
example, in the choroidea and the retinal pigment epi-
thelium of the eye.16 A further essential improvement in
measuring the melanin ﬂuorescence from skin tissue as
selectively as possible could be achieved only recently by
using nanosecond pulses instead of femtosecond
pulses.17
The dermatofluoroscope Magnosco DFC 1 for in vivo
diagnostics of melanoma
The investigational device in this study is the dermato-
ﬂuoroscope Magnosco DFC 1 by Magnosco GmbH,
Berlin, Germany, with a two-photon excitation with
800 nm/nanosecond pulses from a dye laser, equipped
with a spectrometer and a sensitive photon detector. It is
designed for use by dermatologists and trained medical
personnel and should be applied to patients with skin
types I, II, III and IV, who show atypical melanocytic
lesions. For the investigation with the Magnosco DFC 1,
the patient has to be at physical rest. The overview CCD
camera is applied to take a macroscopic image for
documentation reasons. After cleaning and shaving the
location of interest, the lesion is covered with a speciﬁc
cover shield with mask. The latter helps to place the
scanning head onto the intact skin. After ﬁxing it by an
adhesive pad, a dermoscopic image of the lesion is
taken. The spectral data are gathered automatically,
while the lesion is raster-scanned. The results of the data
analysis are presented on the computer screen: (1).
Dermoscopic image overlaid with the scanning raster:
ﬂuorescence spectra indicating malignancy are visualised
as red spots. (2). A score given on a green/red bar
indicates the result of data analysis: (a) presence of
malignant melanoma, (b) no indication of malignant
melanoma, (c) no valid result. The analysis of the spec-
tral data in conjunction with images and patient master
data are documented as one ﬁle in the dermatoﬂuoro-
scope Magnosco DFC 1 database. All ﬁles can be trans-
ferred with the customised USB stick or printed for
patient information.
Preliminary data with the Magnosco DFC 1 device
The preclinical data available for assessing the suitability
of the dermatoﬂuoroscope Magnosco DFC 1 for melan-
oma diagnostics are based on ex vivo and histological
specimen examination. The specimens examined so far
were freshly excised pigmented nevoid lesions and their
corresponding parafﬁn-embedded histological samples.
In 167 freshly excised tissue specimens from clinically
suspicious pigmented lesions (suspected malignant mel-
anoma/dysplastic nevi), the diagnosis was ﬁrst made
based on the new ﬂuorescence-spectroscopic diagnostic
method before the histopathological diagnosis was avail-
able. In relation to the histopathological diagnosis as the
current gold standard of melanoma diagnostics, the new
diagnostic method showed a sensitivity of melanoma
detection of 93.5%, a speciﬁcity of 80.0% and a diagnos-
tic accuracy of 82.6% on freshly excised pigmented
lesions.18 In a study on 125 parafﬁn embedded speci-
mens of melanocytic melanomas (n=60) and melanocy-
tic nevi (n=65), a sensitivity of melanoma detection of
82.5% and a speciﬁcity of 72.5% were detected.19
DESIGN/METHODS
Study design
The FLIMMA study is designed as a prospective, non-
controlled, multicentre clinical study in patients with sus-
pected malignant melanoma.
Objectives
The primary objective of this study is to determine the
sensitivity and speciﬁcity of the algorithm for the ﬂuores-
cence diagnostics of melanoma. The comparator and
gold standard for the diagnosis will be the histopatho-
logical diagnosis of the pigmented lesions. Secondary
objectives are to collect data for training and optimisa-
tion of the diagnostic algorithm, and to assess the safety
of the device and the incidence of adverse events.
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End points
The primary end point is to determine the sensitivity
and speciﬁcity of this fully automated, non-invasive, in
vivo method. Secondary end points include the assess-
ment of the safety of the device as well as the collection
of data for training and optimisation of the compu-
terised diagnostic algorithm.
Recruitment and status of the study
The date of ﬁrst enrolment was 17 September 2014. The
recruitment of patients is in progress. The estimated
total time frame for recruitment of 620 patients is
20 months. The total duration of the study is expected
to be 26 months, including analysis.
Study population
A total of 620 patients, who show pigmented lesions with
suspicion of dysplastic nevus or melanoma and in whom
an excision is indicated, will be recruited.
Criteria for inclusion/exclusion
Patients having pigmented lesions with a suspicion of dys-
plastic nevus or melanoma, in whom an excision is indi-
cated in order to exclude or diagnose malignant
melanoma, who are ≥18 years of age, and who have given
written informed consent will be eligible. Patients with
skin types V and VI according to Fitzpatrick’s scale;
patients where there is a risk that the scanning head is
detached because the patient cannot be placed at rest,
patients who cannot understand the patient information
and who cannot provide informed consent, patients with
deep dermal lesions ≥5 mm beneath the stratum
corneum, clinically or dermoscopically obviously non-
melanocytic lesions, periungual and subungual lesions,
mucosal lesions, lesions with trauma, erosion, excoriation
or ulceration on more than 50% of the lesion area, tat-
tooed lesions, patients suffering from albinism, pregnant
or breastfeeding women, lesions with dominant (>50%)
regression and lesions which are not suitable to ﬁx the
scanning head will be excluded from the FLIMMA study.
Methods
A total of 620 pigmented skin lesions intended for exci-
sion to either conﬁrm or rule out melanoma will be
enrolled after written informed consent at the participat-
ing centres. Three centres participated within Germany:
University Hospital of Tuebingen as the lead centre,
University Hospital of Heidelberg and Charité Berlin.
Clinical and dermoscopic images will be recorded for all
cases. Then, as a second diagnostic procedure, ﬂuores-
cence diagnostics based on the two-photon excitation
from a dye-laser will be performed. The classiﬁcation as
non-melanoma or malignant melanoma by the medical
dermatoﬂuoroscope Magnosco DFC 1 will be documen-
ted prior to the excision. The in vivo melanin ﬂuores-
cence assessment will be performed no longer than
14 days prior to excision. Histopathologists on the study
sites will be blinded to the diagnoses attained by the
analyses of ﬂuorescence spectra. Moreover, all false-
negative cases with a disagreement in the diagnosis by
the test method and the histopathological examination
on site will be submitted to a blinded central pathology
review board. The histopathological diagnosis will serve
as a gold standard for subsequent evaluations of the
diagnostic accuracy. The FLIMMA study was registered at
ClinicalTrials.gov (Identiﬁer: NCT02425475).
Statistical considerations
In this study, 560 evaluable lesions will be recruited,
including 80 evaluable melanomas. In order to compen-
sate for any dropouts, a total of 620 specimens are exam-
ined. It is assumed that the true sensitivity is in the order
of 90%, and the true speciﬁcity is in the order of 35%
based on the available preclinical data described in more
detail in the introduction section. With 70 evaluable mel-
anoma specimens and an observed sensitivity of 90%, the
two-sided 95% CI is 0.80 to 0.96. The speciﬁcity is
assumed to be in the order of 35%, which is evaluated in
420 specimens, according to negative gold standard speci-
men results in a CI of 0.30 to 0.40. This accuracy is con-
sidered sufﬁcient for the method to be evaluated. The
study data and the cohort under evaluation will be ana-
lysed by means of descriptive statistics. Furthermore, the
main end point of the present study is the diagnostic
accuracy. The sensitivity and speciﬁcity of the diagnostic
method of ﬂuorescence-based pigment analysis will be
determined. The comparator and goal standard for this
analysis is the histopathological diagnosis.
ETHICS AND DISSEMINATION
Declarations and ethic aspects
The study is conducted in accordance with the
Declaration of Helsinki principles (2013),20 requirements
and guidance provided in ISO 14155 (2012)21 and applic-
able local government regulations and Independent
Ethics Committee policies and procedures. In the
context of the approved standard operating procedures
which are based on ICH-GCP guidelines (E6) and the
German implementation of Good clinical practice (GCP)
for the clinical work, the patients will be informed orally
and in written form about the aim, character and conse-
quences of the procedure. Before initiation of the study,
the protocol, the patient information sheet and the
consent form were presented to the independent ethics
committee. The names of patients and all conﬁdential
data are subject to professional discretion and the
‘Bundesdatenschutzgesetz (BDSG)’. Processing of
medical data will only take place in pseudonymous form.
In case of withdrawal from the study, the data that have
already been collected will be destroyed. Each participant
will be informed that participation in the study is volun-
tary and that he/she may withdraw from the study at any
time and that withdrawal of consent will not affect his/
her subsequent medical assistance and treatment. The
investigator will explain to each participant the nature of
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the study, its purpose, the procedure involved, the
expected duration, the potential risks and beneﬁts and
any discomfort it may entail. Additionally, all participants
for the study will be provided a participant information
sheet and a consent form describing the study and pro-
viding sufﬁcient information for participants to make an
informed decision about their participation in the study.
The formal consent of a participant, using the approved
consent form, must be obtained before the participant is
submitted to any study procedure. The participant
should read and consider the statement before signing
and dating the informed consent form, and be given a
copy of the signed document. The consent form must
also be signed and dated by the investigator and it will be
retained as part of the study records. All records relating
to this study are stored in an external archive and must
be retained for at least 10 years after completion of the
research.
Risk–benefit relationship
The decision for excision is based on the clinical and der-
moscopic diagnosis of the pigmented lesion, and will not
be biased by the diagnosis of the device under in-
vestigation (dermatoﬂuoroscope Magnosco DFC 1). The
melanin ﬂuorescence measurements of the FLIMMA
study will not inﬂuence the clinical procedures. Therefore,
there is no risk for the patient that his participation may
deteriorate the management rate of his pigmented
lesions. The information of the patient and the measure-
ment procedure itself will generally take <15 min. In case
of a false-negative diagnosis by the dermatoﬂuoroscope
Magnosco DFC, a second independent histopathological
review will be performed. This will be in favour of a higher
diagnostic accuracy and may be beneﬁcial for the patient.
SAFETY
This is a non-invasive diagnostic procedure based on a
low-intensity visible light exposure, which has no cap-
acity to injure tissues. Therefore, no adverse reactions
related to the optical procedures are expected. All
adverse events (AEs) will be recorded and documented.
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